Eli Lilly, one of the largest makers of insulin, said Wednesday it would make dramatic cuts to the prices of several of its older insulin products in an effort to lower costs for consumers whose insulin is not fully paid for by insurance. It also expanded its program to cap out-of-pocket insulin costs at $35 for people who do have health insurance.
The moves come amid a public and political uproar over the price of insulin. Previous moves by the industry have been largely viewed as insufficient and haven’t dulled the controversy around the issue.